Chordate Medical’s CEO, Anders Weilandt, discusses the company’s successes in its focus markets, the exit strategy, and the rights issue in a new interview with Direkt Studios. The subscription period for the rights issue runs from February 2 to February 16.
“We have a strategy that involves firstly building the technology, and that’s done. Secondly, the technology needs to be protected, and we’ve achieved that through patents. Then we have established scientific evidence in several steps—that process is not entirely done, but sufficiently. And now, finally, we will demonstrate that this can be sold and that there is a buying market for it. So that’s our entire focus […] Major global medtech and pharmaceutical players primarily supply their technology portfolio through acquisitions, and we want to be such an example; that’s the whole idea,” says Anders Weilandt in the interview.